Study on Peptide-Mediated Nanomedicine in Tumor Targeting Drugs

Xiangyu Liu

doi:10.47297/taposatWSP2633-456933.20220302

PDF
Export
Share
Collection
Album

Study on Peptide-Mediated Nanomedicine in Tumor Targeting Drugs

Volume 3, Issue 2

Views: 0 Downloads: 4

Study on Peptide-Mediated Nanomedicine in Tumor Targeting Drugs
Study on Peptide-Mediated Nanomedicine in Tumor Targeting Drugs
Second School of Clinical Medicine of Lanzhou University,Gansu,Lanzhou,P.R. China,730000
Vol. 3, Issue 2, Pages: 124-130(2022)
Published： 2022 ，
DOI：10.47297/taposatWSP2633-456933.20220302
Accepted：

Scan QR Code

XIANGYU LIU. (2022). Study on Peptide-Mediated Nanomedicine in Tumor Targeting Drugs. Theory and Practice of Science and Technology, 3(2), 124-130..
DOI：

XIANGYU LIU. (2022). Study on Peptide-Mediated Nanomedicine in Tumor Targeting Drugs. Theory and Practice of Science and Technology, 3(2), 124-130.. DOI： 10.47297/taposatWSP2633-456933.20220302.

摘要

Abstract

With the increasing incidence of cancer

the demand for cancer-related drugs is steadily increasing. However

most of the current drugs for tumors are lack of targeting

and it is difficult to achieve targeted treatment. The development of nanotechnology provides a new idea for this problem. Peptide-mediated nanomedicines can avoid accidental removal through specific obstacles

and finally reach the target. The drug concentration reaching the target increased

and the effectiveness of the drug increased

thus realizing the active targeting function. In this paper

the mechanism of action

specific application and development prospect of polypeptides mediating tumor targeting nano-drugs are discussed.

关键词

Keywords

PeptideTargeted drugAntitumor

references

Yuan Huiyun, Jiang Yufei, Tan Yuting, Xiang Yongbing. “Global cancer incidence and mor-tality prevalence and trends” [J].Tumor control research, 2021,48 (06) : 642-646.[2] Yang Peng. “Advances in research and development of targeted drugs” [J]. Pharmaceutical progress, 2020,44 (09) : 641-643.[3] Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006 Sep;6(9):714-27. doi: 10.1038/nrc1913. PMID: 16929325.[4] Schally AV, Engel JB, Emons G, Block NL, Pinski J. Use of analogs of peptide hormones conjugated to cytotoxic radicals for chemotherapy targeted to receptors on tumors. Curr Drug Deliv. 2011 Jan;8(1):11-25. doi: 10.2174/156720111793663598. PMID: 21034424.[5] Baetke SC, Lammers T, Kiessling F. Applications of nanoparticles for diagnosis and thera-py of cancer. Br J Radiol. 2015 Oct;88(1054):20150207. doi: 10.1259/bjr.20150207. Epub 2015 Jun 12. PMID: 25969868; PMCID: PMC4630860.[6] Xie Yangyang, Wang Shaojuan, Yuan Quan, Xia Ningshao. “New advances in research and application of cell penetrating peptides” [J]. Journal of Bioengineering, 2019,35 (07) : 1162-1173.DOI : 10.13345 / j.cjb.190030.[7] Study on the interaction between cell penetrating peptide CyLoP-1 and heparan sulfate on membrane surface [D]. Lanzhou University, 2020. DOI : 10.27204 / d. cnki. glzhu. 2020.000273.[8] Ponnappan N, Budagavi DP, Chugh A. CyLoP-1: Membrane-active peptide with cell-penetrating and antimicrobial properties. Biochim Biophys Acta Biomembr. 2017 Feb;1859(2):167-176. doi: 10.1016/j.bbamem.2016.11.002. Epub 2016 Nov 9. PMID: 27836642.[9] Aniello F, Colella G, Muscariello G, Lanza A, Ferrara D, Branno M, Minucci S. Expression of four histone lysine-methyltransferases in parotid gland tumors. Anticancer Res. 2006 May-Jun;26(3A):2063-7. PMID: 16827145.[10]Wu Siyu, Zeng Yingrong, Tang Pin, Gui Hui, Hu Lizhi. “The preparation process optimiza-tion and characterization of RGD cyclic peptide modified curcumin/baicalin targeted co-de-livery nanoliposomes” [J]. Chinese herbal medicine, 2021,52 (22) : 6834-6844.[11]Fan Baomin, Hao Chaowei, Wu Jiang, Liu Zhaoxiang, Huang Tao, Lin Chengyuan.A RGD peptide-camptothecin peptide drug conjugate and its application [P].Yunnan Province : CN111068068A, 2020-04-28.[12]Li Juan, Liu Guirong, Qin Haocheng, Wu Jun. “Preparation of paclitaxel-loaded RGD tar-geting peptide polymer ultrasound contrast agent and evaluation of its targeting ability and antitumor effect on breast cancer cells” [J]. Shandong Pharmaceutical, 2021, 61 (17) : 5 – 8.[13]Liu Yang, Jiang Chen. “Research progress on brain targeting of nano drug delivery system” [J]. Journal of Pharmacy, 2013,48 (10) : 1532-1543.DOI : 10.16438 / j.0513-4870.2013.10.002.[14]Blanc E, Bonnafous C, Merida P, Cisternino S, Clair P, Scherrmann JM, Temsamani J. Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel. Anticancer Drugs. 2004 Nov;15(10):947-54. doi: 10.1097/00001813-200411000-00003. PMID: 15514563.[15]Hua D, Tang L, Wang W, Tang S, Yu L, Zhou X, Wang Q, Sun C, Shi C, Luo W, Jiang Z, Li H, Yu S. Improved Antiglioblastoma Activity and BBB Permeability by Conjugation of Paclitaxel to a Cell-Penetrative MMP-2-Cleavable Peptide. Adv Sci (Weinh). 2020 Dec 21;8(3):2001960. doi: 10.1002/advs.202001960. PMID: 33552853; PMCID: PMC7856885.[16]Chen W, Zhan C, Gu B, Meng Q, Wang H, Lu W, Hou H. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J Drug Target. 2011 Apr;19(3):228-34. doi: 10.3109/1061186X.2010.492523. Epub 2010 Jun 14. PMID: 20540685.[17]Gu Z, Chang M, Fan Y, Shi Y, Lin G. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel. Colloids Surf B Biointerfaces. 2017 Dec 1;160:395-405. doi: 10.1016/j.colsurfb.2017.09.052. Epub 2017 Sep 23. PMID: 28965079.[18]Qiao ZY, Zhao WJ, Gao YJ, Cong Y, Zhao L, Hu Z, Wang H. Reconfigurable Peptide Nanotherapeutics at Tumor Microenvironmental pH. ACS Appl Mater Interfaces. 2017 Sep 13;9(36):30426-30436. doi: 10.1021/acsami.7b09033. Epub 2017 Aug 31. PMID: 28828864.[19]Apostolopoulos V, Bojarska J, Chai TT, Elnagdy S, Kaczmarek K, Matsoukas J, New R, Parang K, Lopez OP, Parhiz H, Perera CO, Pickholz M, Remko M, Saviano M, Skwarczynski M, Tang Y, Wolf WM, Yoshiya T, Zabrocki J, Zielenkiewicz P, AlKhazindar M, Barriga V, Kelaidonis K, Sarasia EM, Toth I. A Global Review on Short Peptides: Frontiers and Perspectives. Molecules. 2021 Jan 15;26(2):430. doi: 10.3390/molecules26020430. PMID: 33467522; PMCID: PMC7830668.[20]Jiang Z , Guan J , Qian J , Zhan C . Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomater Sci. 2019 Jan 29;7(2):461-471. doi: 10.1039/c8bm01340c. PMID: 30656305.

Alert me when the article has been cited

Submit

No data

Related Author

No data

Related Institution

No data

⁰